Evidence map›Paper›PMID 27113643›Full record

ReviewInternational journal of obesity (2005)2016

Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations.

A S Kelly, C K Fox, K D Rudser, A C Gross, J R Ryder

Abstract readReview
In one paragraph

Review in International journal of obesity (2005), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Strategies in the Management of Adolescent Obesity.Current pediatrics reports · 2020
    Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

A S KellyDepartment of Pediatrics, University of Minnesota Medical School, and University of Minnesota Masonic Children's Hospital, Minneapolis, MN, USA.
C K FoxDepartment of Pediatrics, University of Minnesota Medical School, and University of Minnesota Masonic Children's Hospital, Minneapolis, MN, USA.
K D RudserDivision of Biostatistics, School of Public Health and Clinical and Translational Science Institute, University of Minnesota, Minneapolis, MN, USA.
A C GrossDepartment of Pediatrics, University of Minnesota Medical School, and University of Minnesota Masonic Children's Hospital, Minneapolis, MN, USA.
J R RyderDepartment of Pediatrics, University of Minnesota Medical School, and University of Minnesota Masonic Children's Hospital, Minneapolis, MN, USA.

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
NCATS NIH HHS UL1 TR000114
6 · The paper itself

Abstract

Despite the increasing number of medications recently approved to treat obesity among adults, few agents have been formally evaluated in children or adolescents for this indication. Moreover, there is a paucity of guidance in the literature addressing best practices with regard to pediatric obesity pharmacotherapy clinical trial design, and only general recommendations have been offered by regulatory agencies on this topic. The purposes of this article are to (1) offer a background of the current state of the field of pediatric obesity medicine, (2) provide a brief review of the literature summarizing pediatric obesity pharmacotherapy clinical trials, and (3) highlight and discuss some of the unique aspects that should be considered when designing and conducting high-quality clinical trials evaluating the safety and efficacy of obesity medications in children and adolescents. Suggestions are offered in the areas of target population and eligibility criteria, clinical trial end-point selection, trial duration, implementation of lifestyle modification therapy and recruitment and retention of participants. Efforts should be made to design and conduct trials appropriately to ensure that high-quality evidence is generated on the safety and efficacy of various medications used to treat pediatric obesity.

Indexed as

Randomized Controlled Trials as TopicAnti-Obesity AgentsBody Mass IndexChildDirective CounselingExenatideHumansHypoglycemic AgentsMetforminPediatric ObesityPeptidesRisk Reduction BehaviorVenomsWeight LossAnti-Obesity AgentsExenatideHypoglycemic AgentsMetforminPeptidesVenoms

Identifiers

PMID27113643
PMCPMC5546093

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.